Prescribing information for more recently approved ALK-inhibitors—ceritinib, lorlatinib, entrectinib, and alectinib—report vision disorders in 4.6% to 21% of patients, including blurred vision, photopsia, and diplopia [51–54]. The gene discussed is ALK; the disease is eye disorder.